

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056745 A2

(51) International Patent Classification⁷: **C07C 233/11**,
235/36, 233/14, 233/23, 233/58, 271/22, 237/20, 233/41,
233/22, 237/22, 233/32, C07D 317/72, 295/088, 207/12,
213/56, A61K 31/165, 31/335, 31/40, 31/44, A61P 3/04,
3/10

(21) International Application Number:
PCT/EP2003/051021

(22) International Filing Date:
16 December 2003 (16.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP02/14832
23 December 2002 (23.12.2002) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-
houtseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LINDERS, Joannes**,
Theodorus, Maria [NL/NL]; Janssen Pharmaceutica N.V.,
Turnhoutseweg 30, B-2340 Beerse (BE). **WILLEMSSENS**,
Gustaaf, Henri, Maria [BE/BE]; Janssen Pharmaceutica
N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **GILIS-**
SEN, Ronaldus, Arnodus, Hendrika, Joseph [NL/BE];
Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340
Beerse (BE). **BUYCK, Christophe, Francis, Robert**,
Nestor [BE/BE]; Janssen Pharmaceutica N.V., Turn-
houtseweg 30, B-2340 Beerse (BE). **VANHOOF, Greta**,

Constantia, Peter [BE/BE]; Janssen Pharmaceutica N.V.,
Turnhoutseweg 30, B-2340 Beerse (BE). **VAN DER**
VEKEN, Louis, Jozef, Elisabeth [BE/BE]; Janssen Phar-
maceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).
JAROSKOVA, Libuse [CZ/BE]; Janssen Pharmaceutica
N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEU-**
TICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

[Continued on next page]

(54) Title: ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS



(57) Abstract: The *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein *n* represents an integer being 1 or 2; *R*¹ and *R*² each independently represents hydrogen *C*₁₋₄alkyl, *NR*⁹*R*¹⁰, *C*₁₋₄alkyloxy; or *R*¹ and *R*² taken together with the carbon atom with which they are attached form a *C*₃₋₆cycloalkyl; and where *n* is 2, either *R*¹ or *R*² may be absent to form an unsaturated bond; *R*³ represents a *C*₆₋₁₂cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or *R*³ represents a monovalent radical having one of the following formulae, wherein said *C*₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of *C*₁₋₄alkyl, *C*₁₋₄alkyloxy, halo or hydroxy; *Q* represents Het¹ or Ar² wherein said *C*₃₋₈cycloalkyl, Het¹ or Ar² are optionally substituted with one or where possible two or more substituents selected from halo, *C*₁₋₄alkyl, *C*₁₋₄alkyloxy, hydroxy, nitro, *NR*⁵*R*⁶, *C*₁₋₄alkyloxy substituted with one or

where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het² and *NR*⁷*R*⁸, and *C*₁₋₄alkyl substituted with one or where possible two or three halo substituents, preferably trifluoromethyl; *R*⁵ and *R*⁶ each independently represent hydrogen, *C*₁₋₄alkyl, or *C*₁₋₄alkyl substituted with phenyl; *R*¹ and *R*⁸ each independently represent hydrogen or *C*₁₋₄alkyl; *R*₉ and *R*₁₀ each independently represent hydrogen, *C*₁₋₄alkyl or *C*₁₋₄alkyloxy; *L* represents *C*₁₋₄alkyl; Het¹ represents a heterocycle selected from pyridinyl, thiophenyl, or 1,3-benzodioxolyl; Het² represents piperidinyl, pyrrolidinyl or morpholinyl; Ar² represents phenyl, naphthyl or indenyl.



PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

— of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.